Clinical Trial

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

Name: A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer — clinical trial record (NCT07474727)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced colorectal cancer, and to assess the PK(Pharmacokinetic) characteristics and immunogenicity of AMT-676.

Trial Details

NCT Number	NCT07474727
Lead Sponsor	Multitude Therapeutics Inc.
Conditions	Colorectal Cancer
Enrollment	180 participants
Start Date	2026-04-01
Primary Completion	2027-09-30 (estimated)
Study Completion	2028-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-03-16